952569-54-9

Usage

Derived from

Isoquinoline (a heterocyclic aromatic compound)

Contains

Iodine atom, methoxy group

Attached to

Isoquinoline ring system

Usage

Building block in the synthesis of pharmaceuticals and other organic compounds

Potential applications

Medicinal chemistry, drug development

Unique

Structure and reactivity

Capable of

Undergoing various chemical reactions to form complex molecules with potential biological activity

Of interest to

Researchers and scientists in the fields of organic chemistry and drug discovery.

Upstream product

• 39989-39-4 7-methoxyisoquinoline 
• 16027-16-0 7-methoxy-2H-isoquinolin-1-one 

Downstream Products

• 1432725-83-1 (2-bromophenyl)(7-methoxyisoquinolin-1-yl)methanone 
• 1432725-84-2 (2-bromo-4,5-dimethoxyphenyl)(7-methoxyisoquinolin-1-yl)methanone 
• 1432725-86-4 (2-bromo-5-trifluoromethylphenyl)(7-methoxyisoquinolin-1-yl)methanone 
• 1432725-66-0 (2-bromophenyl)(7-methoxyisoquinolin-1-yl)acetonitrile 
• 1432725-67-1 (2-bromo-4,5-dimethoxyphenyl)(7-methoxyisoquinolin-1-yl)acetonitrile 
• 1432725-69-3 (2-bromo-5-trifluoromethylphenyl)(7-methoxyisoquinolin-1-yl)acetonitrile 

Relevant academic research and scientific papers

Isoquinoline-based biaryls as a robust scaffold for microtubule inhibitors

We here report the discovery of isoquinoline-based biaryls as a new scaffold for colchicine domain tubulin inhibitors. Colchicinoid inhibitors offer highly desirable cytotoxic and vascular disrupting bioactivities, but their further development requires improving in vivo robustness and tolerability: properties that both depend on the scaffold structure employed. We have developed isoquinoline-based biaryls as a novel scaffold for high-potency tubulin inhibitors, with excellent robustness, druglikeness, and facile late-stage structural diversification, accessible through a tolerant synthetic route. We confirmed their bioactivity mechanism in vitro, developed soluble prodrugs, and established safe in vivo dosing in mice. By addressing several problems facing the current families of inhibitors, we expect that this new scaffold will find a range of in vivo applications towards translational use in cancer therapy.

ISOQUINOLINE BIARYL COMPOUNDS, A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND USES THEREOF

The present invention provides a compound having the formula (I) which is suitable as a tubulin polymerization inhibitor and/or an antimitotic cytotoxin. Thus, it can be employed in the treatment, amelioration or prevention of a disorder selected from a neoplastic disorder, atherosclerosis, psoriasis, restenosis, idiopathic pulmonary fibrosis, scleroderma, wet age-related macular degeneration, and cirrhosis of the liver.

Direct conversion of 1-(2-bromobenzoyl)isoquinolines to dibenzo[ de,g ]quinolin-7-ones via reductive photocyclization

A series of A/D-ring substituted dibenzo[de,g]quinolin-7-ones was produced from the corresponding isoquinolinones and (2-bromophenyl)acetonitriles in four steps. This represents a convenient approach toward the synthesis of tetracyclic alkaloids. A direct conversion of 1-(2-bromobenzoyl)isoquinolines to dibenzo[de,g]quinolin-7-ones is the key step in the total synthesis. The yield of the reductive photocyclization depends on the position of the substituents at the isoquinolyl ring and the phenyl group. The mechanism of the reductive photocyclization is also discussed.

Protic-solvent-mediated cycloisomerization of quinoline and isoquinoline propargylic alcohols: Syntheses of (±)-3-demethoxyerythratidinone and (±)-cocculidine

Putting the benz in indolizinones: A cycloisomerization approach to benz[g]indolizinones and benz[e]indolizinones provides the first general route to these unique azacycles (see example). The utility of the benzindolizinone products was demonstrated by the application of this method to the total synthesis of the Erythrina alkaloids 3-demethoxyerythratidinone and cocculidine. Copyright